UA105503C2 - Похідні 1-аміно-2-циклобутилетилборонової кислоти - Google Patents

Похідні 1-аміно-2-циклобутилетилборонової кислоти

Info

Publication number
UA105503C2
UA105503C2 UAA201105450A UAA201105450A UA105503C2 UA 105503 C2 UA105503 C2 UA 105503C2 UA A201105450 A UAA201105450 A UA A201105450A UA A201105450 A UAA201105450 A UA A201105450A UA 105503 C2 UA105503 C2 UA 105503C2
Authority
UA
Ukraine
Prior art keywords
derivatives
amino
cyclobutylethylboronic
acid
cyclobutylethylboronic acid
Prior art date
Application number
UAA201105450A
Other languages
English (en)
Russian (ru)
Inventor
Пол Е. Флемінг
Цзин Лі
Original Assignee
Мілленніум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мілленніум Фармасьютікалз, Інк. filed Critical Мілленніум Фармасьютікалз, Інк.
Publication of UA105503C2 publication Critical patent/UA105503C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)

Abstract

У даному винаході пропонуються сполуки, придатні як інгібітори протеасом.У винаході також пропонуються фармацевтичні композиції, що містять сполуки за винаходом, і способи застосування композицій в лікуванні різноманітних захворювань.
UAA201105450A 2008-09-29 2009-09-25 Похідні 1-аміно-2-циклобутилетилборонової кислоти UA105503C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
PCT/US2009/005324 WO2010036357A1 (en) 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Publications (1)

Publication Number Publication Date
UA105503C2 true UA105503C2 (uk) 2014-05-26

Family

ID=41426361

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201105450A UA105503C2 (uk) 2008-09-29 2009-09-25 Похідні 1-аміно-2-циклобутилетилборонової кислоти

Country Status (25)

Country Link
US (3) US8664200B2 (uk)
EP (1) EP2346882B1 (uk)
JP (3) JP5736314B2 (uk)
KR (1) KR101739470B1 (uk)
CN (2) CN102203103A (uk)
AR (1) AR075090A1 (uk)
AU (1) AU2009297113B2 (uk)
BR (1) BRPI0919447B8 (uk)
CA (1) CA2739375C (uk)
CL (1) CL2011000653A1 (uk)
CO (1) CO6362015A2 (uk)
CR (2) CR20160475A (uk)
DO (1) DOP2011000086A (uk)
EA (1) EA030539B1 (uk)
EC (1) ECSP11011011A (uk)
IL (1) IL211983A0 (uk)
MA (1) MA32729B1 (uk)
MX (1) MX2011003317A (uk)
MY (1) MY166653A (uk)
NZ (2) NZ592497A (uk)
SG (1) SG194388A1 (uk)
TW (2) TWI598352B (uk)
UA (1) UA105503C2 (uk)
WO (1) WO2010036357A1 (uk)
ZA (1) ZA201203615B (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056464A1 (en) 2005-11-09 2007-05-18 Proteolix, Inc. Compounds for enzyme inhibition
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
NZ598436A (en) 2007-10-04 2014-03-28 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
CN107266480A (zh) 2008-06-17 2017-10-20 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
MX368109B (es) 2008-10-21 2019-09-18 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CN104321060B (zh) 2011-12-22 2018-08-07 阿雷斯贸易股份有限公司 α-氨基硼酸衍生物，选择性免疫蛋白酶体抑制剂
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
MX2015006715A (es) * 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
EP3052105A1 (en) 2013-10-03 2016-08-10 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
CR20160577A (es) 2014-05-20 2017-01-06 Millennium Pharm Inc Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria
EP3808349B1 (en) 2014-08-07 2022-10-05 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016028571A2 (en) 2014-08-18 2016-02-25 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
EP3201205B1 (en) * 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
SG11201702623TA (en) * 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
JP6896618B2 (ja) * 2014-10-01 2021-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
CN107001391B (zh) * 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
KR102764027B1 (ko) 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
KR102595723B1 (ko) 2016-06-21 2023-10-27 오리온 옵탈몰로지 엘엘씨 헤테로시클릭 프롤린아미드 유도체
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
CA3054572A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN114040915B (zh) 2019-04-12 2025-07-15 里伯赛恩斯有限责任公司 作为外核苷酸焦磷酸酶磷酸二酯酶1抑制剂的双环杂芳基衍生物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ES2098484T3 (es) 1992-08-14 1997-05-01 Procter & Gamble Detergentes liquidos que contienen un acido alfa-amino-boronico.
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
IL131410A0 (en) 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
TR201819416T4 (tr) 2001-01-25 2019-01-21 The United States Of America Represented By The Sec Dep Of Health And Human Services Boronik asit bileşiklerinin formülasyonu.
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003105860A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
EP4008721B1 (en) 2004-03-30 2024-01-03 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
RS52435B (sr) 2007-08-06 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori proteazoma
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CN107266480A (zh) 2008-06-17 2017-10-20 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
CN102892291A (zh) 2010-03-31 2013-01-23 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物

Also Published As

Publication number Publication date
CN102203103A (zh) 2011-09-28
EA201170508A1 (ru) 2011-10-31
CO6362015A2 (es) 2012-01-20
CN103554143A (zh) 2014-02-05
NZ606001A (en) 2014-08-29
BRPI0919447A2 (pt) 2015-12-15
JP2015143264A (ja) 2015-08-06
MY166653A (en) 2018-07-18
EA030539B1 (ru) 2018-08-31
JP5736314B2 (ja) 2015-06-17
CA2739375A1 (en) 2010-04-01
US10035811B2 (en) 2018-07-31
KR20110082534A (ko) 2011-07-19
AU2009297113B2 (en) 2016-11-10
CN103554143B (zh) 2018-02-23
US20140194387A1 (en) 2014-07-10
AR075090A1 (es) 2011-03-09
US9771381B2 (en) 2017-09-26
WO2010036357A1 (en) 2010-04-01
TW201641504A (zh) 2016-12-01
MA32729B1 (fr) 2011-10-02
MX2011003317A (es) 2011-04-26
ZA201203615B (en) 2015-03-25
IL211983A0 (en) 2011-06-30
JP2017025091A (ja) 2017-02-02
CL2011000653A1 (es) 2011-09-30
CA2739375C (en) 2019-03-12
BRPI0919447B1 (pt) 2021-03-30
KR101739470B1 (ko) 2017-05-24
SG194388A1 (en) 2013-11-29
TW201024313A (en) 2010-07-01
US20170349611A1 (en) 2017-12-07
US20100081633A1 (en) 2010-04-01
DOP2011000086A (es) 2011-04-15
NZ592497A (en) 2013-02-22
US8664200B2 (en) 2014-03-04
EP2346882B1 (en) 2017-09-20
ECSP11011011A (es) 2011-07-29
BRPI0919447B8 (pt) 2021-05-25
JP2012504122A (ja) 2012-02-16
AU2009297113A1 (en) 2010-04-01
TWI598352B (zh) 2017-09-11
CR20160475A (es) 2016-12-19
EP2346882A1 (en) 2011-07-27
CR20110216A (es) 2011-07-14

Similar Documents

Publication Publication Date Title
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12014500053A1 (en) Proteasome inhibitors
PH12015501191A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
CA2818187C (en) Bromodomain inhibitors and uses thereof
IN2012DN00971A (uk)
TN2010000203A1 (en) Beta-lactamase inhibitors
CA2871471C (en) Dna-pk inhibitors
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
IN2014DN10386A (uk)
EA201170832A1 (ru) Пуриновые соединения
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MY180594A (en) Proteasome inhibitors
UA106205C2 (uk) Сполуки боронатного ефіру, фармацевтична композиція (варіанти), яка містить їх, і спосіб їх одержання (варіанти)
EA201791835A2 (ru) Ингибиторы протеасом